Navigation Links
Researchers Design Promising Cancer Drug
Date:3/7/2008

It activates p53 tumor-suppressor function without causing DNA damage

FRIDAY, March 7 (HealthDay News) -- A drug that targets a protein interaction involved in many types of cancer has been created by University of Michigan researchers.

In cell cultures, the small-molecule inhibitor MI-219 was highly effective at preventing the tumor-suppressor function of the protein p53 from being blocked in the presence of a protein called MDM2.

In animals with human cancer, MI-219 completely inhibited tumor growth and appeared to cause no severe side effects.

"For more than 10 years, scientists have searched for ways to block p53 inhibition, but with little success. Our study clearly shows that this can be done," study author Shaomeng Wang, a professor of medicine at the U-M Medical School and co-director of the molecular therapeutics program at the U-M Comprehensive Cancer Center, said in a prepared statement.

The research was published online this week in the Proceedings of the National Academy of Sciences.

Clinical trials of the drug could begin by the end of 2008. If the drug proves safe and effective in humans, it could potentially be used to treat many kinds of cancer, according to the researchers.

In almost all types of human cancer, p53 is inactivated. About half the time, this is because the protein MDM2 binds to p53 and inhibits the tumor-suppressor function of p53. In other cases, p53 dysfunction is due to a missing or mutated gene.

"Many traditional cancer drugs also activate p53, but they do so by causing DNA damage. They kill not only tumor cells but also normal cells, thus having severe side effects. MI-219 is unique in that it is designed to activate p53 without causing DNA damage, specifically killing tumor cells," Wang said.

The University of Michigan has filed a patent application for MI-219 and its related molecules. The technology has been licensed by
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Case Western Reserve University researchers identify colorectal cancer gene
2. On a roll: MIT researchers devise new cell-sorting system
3. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
4. Researchers control growth rate of replacement blood vessels, tissues
5. New protein discovery helps researchers understand autoimmune diseases
6. UF researchers warn parents about dangers of childhood foot burns
7. UCLA researchers find blood stem cells originate and are nurtured in the placenta
8. UCSF researchers validate new model for breast cancer risk assessment in multiple ethnic groups
9. Einstein researchers discover gene mutations linked to longer lifespans
10. U-M researchers ID promising new cancer drug
11. Researchers identify new genetic marker for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers Design Promising Cancer Drug
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules ... mesothelioma that looks and acts similar to asbestos-induced mesothelioma. ... the research. Click here to read it now. ... and Experimental Medicine in Hannover injected 500 lab rats ... rats eventually developed mesothelioma , how quickly it ...
(Date:11/26/2014)... Loffler Companies has been selected as ... an online information and news publication for resellers of ... consecutive year Loffler has earned this prestigious award and ... Dealer Awards honor the best and the brightest in ... honorees were chosen for their innovative marketing and sales ...
(Date:11/26/2014)... 2014 Senior Planning Services, providing “expert ... nonprofit organization providing the adult demographic education and ... seniors navigate the rough seas of applying for Medicaid. ... on the topic of Medicaid eligibility and proper planning, ... of applying for this coverage. , Senior Planning ...
(Date:11/26/2014)... Call 866-997-4948 (Us-Canada Toll Free) Tel: ... details on sales(at)researchmoz(dot)us , Researchmoz.us announces a new ... 2014" with deep study of the report on the ... blood sugar. The global glucose monitoring market has a ... number of diabetics in the world. Their numbers have ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Louisiana ... relief and specialists in minimally invasive spine surgery, ... Shamieh into the rapidly growing provider network of ... The addition coincides with the network’s continuing success ... treatment for Louisiana residents who are suffering from ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... BOSTON Postmenopausal women who reported having used nonsteroidal ... time of enrollment in the Women,s Health Initiative study ... compared with women who reported no use of these ... 10th AACR International Conference on Frontiers in Cancer Prevention ...
... Institute (HCI) at the University of Utah have discovered a ... to new tools for predicting which breast cancers will spread ... spread. Their results are published online today in the journal ... for breast cancer studies, the researchers grafted tumor tissue from ...
... working night shifts may be compromising their own health ... Dr. Joan Tranmer told the Canadian Cardiovascular Congress 2011, ... Canadian Cardiovascular Society. Dr. Tranmer,s study investigated the ... disease in female hospital employees who worked both shift ...
... By Randy Dotinga HealthDay Reporter , FRIDAY, Oct. ... staple of professional ice hockey games, but are they as ... punches thrown during National Hockey League games end in significant ... isn,t particularly dangerous, possibly because it,s hard to get traction ...
... known as the PSA test, is valuable in predicting which ... diagnosed with low-risk prostate cancer, a Mayo Clinic study has ... the North Central Section of the American Urological Association ( ... decision to use the PSA test is best made by ...
... that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans ... tool in prostate cancer. The results of three studies, ... Section of the American Urological Association ( http://www.ncsaua.org/default.aspx ), ... of C-11 choline PET scans. One study ...
Cached Medicine News:Health News:NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women 2Health News:Will my breast cancer spread? Discovery may predict probability of metastasis 2Health News:Female shift workers may be at higher risk of heart disease 2Health News:Female shift workers may be at higher risk of heart disease 3Health News:Hockey Fistfights Rarely Cause Injuries, Study Claims 2Health News:Hockey Fistfights Rarely Cause Injuries, Study Claims 3Health News:Mayo Clinic study: PSA test valuable in predicting biopsy need, low-risk prostate cancer 2Health News:Trio of studies support use of PET/CT scans as prostate cancer staging tool 2
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
(Date:11/26/2014)... , Nov. 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China ... today announced the appointment of Ms. Rebecca Yingnan ... immediately. Ms.Zhang has over 20 years ... in March 1999. Prior to Ms. Zhang,s appointment as ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: